98%
921
2 minutes
20
Purpose: R0 resection with a wide surgical margin is the gold standard for hepatocellular carcinoma (HCC), yet R0 resection with narrow margins and even R1 resection is not uncommon in real-world clinical practice. We sought to use a propensity-matched analysis to characterize the efficacy of adjuvant radiation therapy on long-term oncological survival after hepatectomy for HCC with narrow or positive margins.
Methods And Materials: Using a multi-institutional database, patients with HCC who underwent hepatectomy with negative margins of 0.1 to 1.0 cm or pathologically positive margins were analyzed. Using propensity score matching (PSM) and multivariate Cox-regression analysis, the effect of adjuvant radiation therapy on long-term overall survival (OS) and recurrence-free survival (RFS) was evaluated.
Results: Among 683 patients who met inclusion criteria, 82 patients received adjuvant radiation therapy within 10 weeks after surgery. Radiation therapy-related major toxic effects were minimal among patients receiving adjuvant radiation therapy. PSM analysis created 78 matched pairs of patients. In the PSM cohort, median OS and RFS among patients treated with adjuvant radiation therapy were more favorable than individuals who were not treated (72.5 and 37.3 months versus 52.5 and 24.0 months, both P < .05). After adjustment for other confounding factors on multivariate analyses, adjuvant radiation therapy remained independently associated with favorable OS and RFS after hepatectomy with close/positive surgical margins for HCC (hazard ratios, 0.821 and 0.827, respectively).
Conclusions: Despite the lack of consensus on the role of adjuvant radiation therapy after HCC resection, this PSM analysis suggested improved OS and RFS with adjuvant radiation therapy after hepatectomy with close/positive surgical margins for HCC. Future randomized controlled trials are needed to further define the survival benefit of adjuvant radiation therapy for patients with HCC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijrobp.2022.05.020 | DOI Listing |
JPRAS Open
September 2025
Department of Plastic and Aesthetic Surgery, Dongguan Kanghua Hospital, Guangdong, China.
Background: Keloids, pathological scars with complex etiology including genetic predisposition and trauma, remain a therapeutic challenge due to high recurrence rates. This study intends to conduct a retrospective study on the patients who received punch drilling therapy for keloid in our hospital to provide a new method and objective basis for the treatment of keloid.
Methods: A retrospective analysis of 13 patients (20 keloids) treated at Dermatology Hospital of Southern Medical University was conducted.
Cancer Rep (Hoboken)
September 2025
ENT and Head and Neck Research Center and Department, the Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Objective: To present a case of metastatic endometrial carcinosarcoma (ECS) with a long-term complete response to chemotherapy using a paclitaxel and carboplatin regimen.
Case Report: A 47-year-old premenopausal woman was diagnosed with a large, advanced intrauterine tumor. She underwent a total abdominal hysterectomy with bilateral salpingo-oophorectomy.
Food Res Int
November 2025
Research Laboratory, Tibetan Hospital of Naqu, Tibetan, China. Electronic address:
Chronic high-altitude disease (CHAD) is primarily driven by oxidative damage and inflammation. Hydrogen-rich water (HRW) is a novel functional food with demonstrated antioxidant and anti-inflammatory properties. However, its potential effects on inflammation and oxidative stress in CHAD remain unexplored.
View Article and Find Full Text PDFLancet Oncol
September 2025
Department of Radiation Oncology, Leiden University Medical Centre, Leiden, Netherlands.
Background: The PORTEC-3 trial investigated the benefit of chemoradiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer. We present the preplanned long-term analysis of the randomised PORTEC-3 trial with a post-hoc analysis including molecular classification of the tumours.
Methods: PORTEC-3 was an open-label, multicentre, randomised, international phase 3 trial.
PLoS One
September 2025
Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Background: Our study represents the first effort in the Eastern Mediterranean Region to identify disparities in the quality of colorectal cancer (CRC) care in Iran.
Methods: We established a collaborative registry program for non-metastatic CRC patients to evaluate survival rates between teaching cancer centers (TCCs) and a high-volume, non-teaching, non-cancer center (NTNC). The study included a diverse patient population and considered various factors such as cancer stage, margin involvement, adherence to guidelines for adjuvant and neoadjuvant treatments, emergency surgeries, socioeconomic status, and risk of surgery.